RespireRx Pharmaceuticals Inc (RSPI)

[K-G]

I recall Stoll saying at some point when he was discussing the near miss at partnering ADHD that the company was surprised that there was more interest by potential partners in neurodegenerative use for CX717 (perhaps not CX717 alone) than in ADHD. This combined with the obvious desire of the FDA for Cortex to persue a higher morbidity indication than ADHD for the first use of an Ampakine, I believe is the most obvious spot to question management decision making. There was clearly an opportunity to partner for AD, though I'm sure the $ were less than they wanted at the time. The biggest 'mistake' as I see it, is the failure to fully understand the FDA requirements for getting CX717 approved for further testing. They and their high paid consultants definately missed the boat here. I have no idea whether better communication with the FDA was possible (the FDA was very over-loaded at the time), but I hope that they didn't quit pressing for more information during the long period for the assembly of the 6 foot box of data.